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Evaluation of Electrolyte Repletion and Infection Rates in
Hematopoietic Cell Transplant Patients Receiving H-2
Receptor Antagonists or Proton Pump Inhibitors
Katelyn Smith 1, Mandy Gatesman 1, May Aziz 1, William Clark 2,
Spencer Harpe 1. 1 Pharmacy, Virginia Commonwealth
University, Richmond, VA; 2 Internal Medicine, Virginia
Commonwealth University, Richmond, VA
At Virginia Commonwealth University Health System, he-
matopoietic cell transplant (HCT) patients receive proton
pump inhibitors (PPI) during their admission to prevent
chemotherapy-induced gastroduodenal injury. Prior to 2012,
most patients were also discharged on PPI to reduce the
frequency of ulcers and upper gastrointestinal (GI) symp-
toms after HCT.
Adverse effects of PPI therapy may include magnesium
deﬁciency, 1,2 increases in Clostridium difﬁcile infection,3 and
an increased risk of community-acquired pneumonia.4
Compared to PPI therapy, H-2 receptor antagonists (H2RA)
have less pronounced and prolonged acid suppressionwhich
contributes to an advantageous side effect proﬁle. Since HCT
patients are subject to low electrolyte levels5 and increased
risks of infection at baseline, we sought to determine the
association between PPI use and electrolyte repletion and
infection rates and whether the use of H2RA was associated
with reduced risk of these complications.
A retrospective, matched cohort study was conducted
from September 30, 2010 through March 31, 2013. Patients
18 years or older receiving H2RA therapy post-HCT
admission were matched by transplant type and prepara-
tory regimen to patients receiving PPI. Matched pairs were
evaluated for four weeks post-discharge. In addition to
baseline characteristics, data collected included the
amount and frequency of electrolyte repletion via a stan-
dard institutional protocol, rates of infection (positive
cultures, use of antibiotics, radiologic evidence of pneu-
monia), and patient-reported GI symptoms. Data were
analyzed with descriptive statistics, paired t-tests, and
McNemar’s Chi square test.
Twenty-six matched pairs were included. Patients receiving
PPI required signiﬁcantly more magnesium repletion in
weeks 1, 3, and 4 post-discharge. During weeks 1, 3, and 4,
signiﬁcantly more patients receiving H2RA therapy went an
entire week without repletion versus patients receiving PPI.
Although the magnitude or frequency of potassium or cal-
cium repletion were generally higher among PPI users, these
differences were not statistically signiﬁcant. The number of
patients with evidence of infection was not signiﬁcantly
different between groups. Compared to patients on H2RA
therapy, signiﬁcantly more patients receiving PPI reported GI
symptoms.
H2RA therapy deserves serious consideration in place of PPI,
when possible, for HCT patients post-discharge.
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Background: Multidisciplinary collaboration leads to
improvement in pt outcomes when clinical pharmas are
engaged in various settings. Clinical pharma integration in
the BMT setting has increased as these programs expand.
There is an absence of literature deﬁning the beneﬁt of
clinical pharma involvement in this area of practice. UMass
Memorial Medical Center is a large academic medical center
performing 108 allogenic transplants since 2010. In August
2010, the medical center implemented the integration of a
health-system clinical pharma to the BMT team. This study
aims to determine the impact of a health- system based
clinical pharma on pt outcomes and associated costs in the
BMT setting.
Methods: Records for pts receiving an allogeneic stem cell
transplant (ASCT) from January 2008 to August 2012 were
reviewed. The primary outcome measure was difference in
length of stay (LOS) for ASCT prior to and after pharma
integration on the BMT team. Secondary outcome measures
include number of readmissions within 30 days, overall
survival at 100 days, duration of intravenous (IV) antimi-
crobial therapy, duration of IV immunosuppressive therapy
(IST), and duration of oral IST.
Results: 106 pts were identiﬁed and included for analysis. 45
were transplanted prior to pharmacist implementation and
61 were after BMT. Baseline demographics were similar be-
tween the two groups. In the pre and post group, the most
common indication for transplant was AML (40% vs. 51%) and
the most common source was a matched unrelated donor
(60% vs. 62%). The majority of pts in both groups received
myeloablative regimens (80% vs. 69%). LOS was decreased in
the after group but was not statistically signiﬁcant (24.8 vs.
22.9 days, p¼ 0.43).100-day survival (80% vs. 88.5%, p¼0.23)
and readmission within thirty days were not signiﬁcantly
changed (42.2% vs. 37.7%, p¼0.64). Days of IV antibacterials,
antivirals and antifungals were all decreased, but were not
statistically signiﬁcant. Days on IV IST were signiﬁcantly
decreased (21.4 vs. 11.3 days, p¼0.001) showing a reciprocal
increase in oral IST use (4.9 vs. 9.1 days, p¼0.001). Costs
beneﬁts were assessed using 2013 WAC prices. Cost savings
were reported as $3,083 per pt, for a total beneﬁt since
implementation of $184,985 or $92,493 per year.
Conclusion: Our analysis demonstrates signiﬁcant im-
provements in cost saving with the implementation of a
pharma in the BMT setting, speciﬁcally allogeneic pts. While
Table 1
Results Fosaprepitant vs. Control, Overall Assessment Period
Control
(n¼70)
FOS
(n¼43)
No emesis (%) 65.7 81.4
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decreased LOS, readmission at 30 days, and use of antimi-
crobials. Use of IV IST were signiﬁcantly decreased. Incor-
poration of clinical pharma should be strongly considered in
this pt population.Day(s) of melphalan (%) 98 99
Days 1-5 post-melphalan (%) 66 84
Complete response (%)
(no emesis or breakthrough antiemetic use)
1.4 4.7
Emetic episode per patient (mean) 0.76 0.28
Breakthrough antiemetic doses per patient (mean) 9.6 9.98
Complete protection (%)
(no emesis, breakthrough antiemetics,
or signiﬁcant nausea)
- 9.7*
No nausea (%)
(<5 mm on 100 mm VAS)
- 16.1*
No signiﬁcant nausea (%)
(<25 mm on 100 mm VAS)
- 35.5*
*For 31 evaluable subjects446
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Graft-versus-host-disease (GVHD) is a life threatening
complication of allogeneic hematopoietic stem cell trans-
plantation (HSCT). The calcineurin inhibitor tacrolimus is
commonly used in combination with other immunosup-
pressants to prevent GVHD; however the optimal serum
target concentration for tacrolimus in this population re-
mains unknown. A retrospective review was conducted to
determine whether an association exists between tacrolimus
concentrations and transplant-related outcomes, speciﬁcally
acute GVHD, as well as the rate of renal toxicity and mor-
tality. Data from 203 patients who underwent an allogeneic
HSCT from a related (n¼95) or unrelated (n¼108) donor
between January 1, 2003 and December 31, 2011 at a large
academic hospital was analyzed. Sixty-two (31%) patients
developed acute GVHD within the ﬁrst 30 days following
allogeneic stem cell transplant. Median tacrolimus concen-
trations at day 0, 7, 14, and 28 were 11.2, 13.8, 13.5 and 10.2
ng/mL, respectively among those who developed acute
GVHD. Patients who did not develop acute GVHD had similar
tacrolimus concentrations of 10.4,13.1,12.3 and 9.9 ng/mL for
the same respective time points. Serum tacrolimus concen-
trationswere similar across all grades of GVHD and therewas
no correlation between drug concentrations with respect to
renal toxicity. Patients who developed renal dysfunction
(n¼18) had tacrolimus concentrations similar to the median
concentration of the entire cohort, including those who did
not experience renal toxicity. Overall mortality among the
203 included patients was 49%. Mortality was higher among
patients who developed acute GVHD (55%) than in patients
who did not experience the disease (47%). The results of this
analysis support previous conclusions that tacrolimus blood
concentrations are not associated with acute GVHD within
the ﬁrst 30 days post allogeneic HSCT.447
Fosaprepitant for the Prevention of Nausea and Vomiting
in Patients Receiving BEAM or High-Dose Melphalan
Conditioning Regimens for Autologous Hematopoietic
Stem Cell Transplantation
Stephen M. Clark 1,2, Lindsay Schaack 2, David DeRemer 1,2,
Vamsi Kota 1, Amber Bradley Clemmons 1,2. 1 Georgia Regents
Medical Center, Augusta, GA; 2University of Georgia College of
Pharmacy, Augusta, GA
Chemotherapy-induced nausea and vomiting (CINV) occurs
frequently during hematopoietic stem cell transplantation
(HSCT) despite prophylactic therapy with serotonin antago-
nists and corticosteroids. Aprepitant, an oral neurokinin-1
(NK1) inhibitor, has been considered as add-on prophylactic
therapy; however, to date no published studies have inves-
tigated the injectable NK1 inhibitor fosaprepitant (FOS) in
HSCT. The purpose of this study is to assess the ability of FOSto reduce emesis after BEAM and high-dose melphalan
autologous HSCT.
The use of a 150 mg fosaprepitant IV x 1 prior to melphalan
became standard practice at our institution in the summer of
2012 for BEAM and high-dose melphalan regimens. We
performed an IRB approved cohort study comparing patients
who prospectively receive FOS to a historical cohort who did
not receive FOS. The primary endpoint was overall percent-
age of patients with no emesis during the assessment period
(ﬁrst day of melphalan through ﬁve days after melphalan
administration). Secondary endpoints include number of
emetic episodes per patient, number of breakthrough anti-
emetic doses per patient, and complete response rate (no
emesis or breakthrough antiemetic use). Patients in the FOS
cohort also recorded nausea on a 100 mm visual analog scale
(VAS) daily allowing for additional exploratory endpoints of
complete protection rate (complete response plus no sig-
niﬁcant nausea), no signiﬁcant nausea (< 25 mm on 100 mm
VAS), and no nausea (< 5mmon 100mmVAS) to be assessed
for that single cohort. A sample size of 70 patients per cohort
was deemed necessary based on an estimated 40% no emesis
in control group for 80% power at alpha¼0.05 to detect a 25%
absolute increase in patients with no emesis.
Seventy consecutive patients who received BEAM or high-
dose melphalan without FOS were included in the historical
cohort and 43 patients have received FOS in the prospective
cohort. Interim results suggest the addition of FOS improved
the percentage of patients with no emesis and the number of
emetic episodes per patient. Exploratory endpoints in the
FOS cohort which included patient reported nausea assess-
ments on a VAS are encouraging as a third of patients re-
ported no signiﬁcant nausea during the overall assessment
period. Based on these promising interim results, enrollment
in the FOS cohort is ongoing.448
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Anti-thymocyte globulin (ATG) during conditioning for
allogeneic HSCT is often accompanied by infusion reactions;
